Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Institut Pasteur Korea Selects ActivityBase™ as its Screening Solution of Choice

Published: Tuesday, September 19, 2006
Last Updated: Tuesday, September 19, 2006
Bookmark and Share
New Research Center in Korea employs ActivityBase for High Content Screening.

IDBS has announced that Institut Pasteur - Korea has implemented the ActivityBase data management software suite to increase efficiency and throughput in its screening operations.

Institut Pasteur Korea (IP-K), a Research Center located in Seoul, South Korea, has purchased ActivityBase to handle their biology and chemistry data for High Throughput and High Content Screening (HTS/HCS).

IP-K is implementing HCS assays and platforms for Drug Discovery using cell-based models of disease and automated confocal microscopy.

IP-K will use ActivityBase suite to consolidate chemistry information and screening results, including those from microscopy-based screens, in a single Oracle database.

Institut Pasteur Korea decided to purchase ActivityBase as its researchers felt more secure with a system with a proven track record in Drug Discovery.

Dr. Thierry Christophe, the Head of the Screening and Pharmacology lab, has used ActivityBase in previous positions at other companies.

He said, "I am happy to be working with ActivityBase again, as it is a robust and flexible system that I know can deliver the results we need."

"We plan to develop specific data analysis templates for High Content Screens allowing the manipulation of multiplexing data from one single screen."

Neil Kipling, IDBS’ Chairman and CEO, commented, "The increase in HCS and HTS planned by IP-K’s screening group demanded a data management system that could scale up to their requirements, both now and in the future, as well as map closely to their workflow."

"We are delighted to be supporting a centre of excellence in biomedical research and technology development, allowing new drugs to be identified faster and more reliably."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!